Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,totalCurrentAssets,longTermInvestments,netReceivables,accountsPayable,otherLiab,changeToLiabilities,WC,language,region,quoteType,triggerable,quoteSourceName,dividendDate,regularMarketChangePercent,regularMarketDayRange,ask,bid,regularMarketPreviousClose,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,currency,marketState,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,exchangeDataDelayedBy,twoHundredDayAverageChangePercent,shortName,exchange,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,HQL,502677966.0,24279400,,,15773640,,15773640,1564727,554310,-1010417,-1010417,,,,,,0,554310,1564727,0,16784057,,15773640,15773640,364247380.0,649627.0,502677966.0,503327593.0,242794.0,1047000.0,138187792.0,33726293.0,159.0,649627.0,1176700.0,468424600.0,85734.0,44080.0,,0,527073.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1546214400,0.09153527,21.8276 - 22.02,0.0,0.0,21.85,10,13,finmb_352795,NYSE,Tekla Life Sciences Investors,USD,71673,73871,5.2700005,0.3174699,16.6 - 22.7,-0.8299999,-0.036563873,16.6,22.7,1.58,4.26815,0.072311215,USD,PRE,21.87,1630526402,0.020000458,21.95,22.02,21.8276,59448,us_market,2,0,0.06066922,TeklaLife Sciences Investors,NYQ,5.124,20.704,21.343714,0.5262871,0.02465771,20.619059,1.2509422,530990496,1.0563177,15,America/New_York,EDT,-14400000,False,False,0.95,,,22.7,16.6,21.34,20.62,71.67k,73.87k,24.28M,,,0.00%,19.87%,44.37k,0.53,,0.18%,54.08k,1.64,7.88%,1.58,7.23%,8.76,30.33%,"Dec 30, 2018","May 26, 2021",,,"Sep 29, 2020","Mar 30, 2021","5,360.98%",-158.21%,-0.51%,27.52%,2.32M,0.10,-49.10%,3.39M,,124.41M,5.12,4.50%,159.0,0.0,,,1.81,20.7,,,Value,02110,Financial Services,"Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.",Boston,617-772-8500,MA,1388448000,United States,http://www.teklacap.com/hql.html,86400,100 Federal Street,617-772-8577,Asset Management,19th Floor
t-1,HQL,502677966.0,24279400,,,15773640,,15773640,1564727,554310,-1010417,-1010417,,,,,,0,554310,1564727,0,16784057,,15773640,15773640,364247380.0,649627.0,502677966.0,503327593.0,242794.0,1047000.0,138187792.0,33726293.0,159.0,649627.0,1176700.0,468424600.0,85734.0,44080.0,,0,527073.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1546214400,0.09153527,21.8276 - 22.02,0.0,0.0,21.85,10,13,finmb_352795,NYSE,Tekla Life Sciences Investors,USD,71673,73871,5.2700005,0.3174699,16.6 - 22.7,-0.8299999,-0.036563873,16.6,22.7,1.58,4.26815,0.072311215,USD,PRE,21.87,1630526402,0.020000458,21.95,22.02,21.8276,59448,us_market,2,0,0.06066922,TeklaLife Sciences Investors,NYQ,5.124,20.704,21.343714,0.5262871,0.02465771,20.619059,1.2509422,530990496,1.0563177,15,America/New_York,EDT,-14400000,False,False,0.95,,,22.7,16.6,21.34,20.62,71.67k,73.87k,24.28M,,,0.00%,19.87%,44.37k,0.53,,0.18%,54.08k,1.64,7.88%,1.58,7.23%,8.76,30.33%,"Dec 30, 2018","May 26, 2021",,,"Sep 29, 2020","Mar 30, 2021","5,360.98%",-158.21%,-0.51%,27.52%,2.32M,0.10,-49.10%,3.39M,,124.41M,5.12,4.50%,159.0,0.0,,,1.81,20.7,,,Value,02110,Financial Services,"Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.",Boston,617-772-8500,MA,1388448000,United States,http://www.teklacap.com/hql.html,86400,100 Federal Street,617-772-8577,Asset Management,19th Floor
t-2,HQL,483570376.0,24279400,,,46430732,,46430732,1431334,606009,-825325,-825325,,,,,,0,606009,1431334,0,47256058,,46430732,46430732,356301677.0,595185.0,483570376.0,484165561.0,238832.0,4966000.0,127029867.0,59642860.0,,581242.0,5158511.0,419364190.0,165559.0,,13943.0,0,4577269.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1546214400,0.09153527,21.8276 - 22.02,0.0,0.0,21.85,10,13,finmb_352795,NYSE,Tekla Life Sciences Investors,USD,71673,73871,5.2700005,0.3174699,16.6 - 22.7,-0.8299999,-0.036563873,16.6,22.7,1.58,4.26815,0.072311215,USD,PRE,21.87,1630526402,0.020000458,21.95,22.02,21.8276,59448,us_market,2,0,0.06066922,TeklaLife Sciences Investors,NYQ,5.124,20.704,21.343714,0.5262871,0.02465771,20.619059,1.2509422,530990496,1.0563177,15,America/New_York,EDT,-14400000,False,False,0.95,,,22.7,16.6,21.34,20.62,71.67k,73.87k,24.28M,,,0.00%,19.87%,44.37k,0.53,,0.18%,54.08k,1.64,7.88%,1.58,7.23%,8.76,30.33%,"Dec 30, 2018","May 26, 2021",,,"Sep 29, 2020","Mar 30, 2021","5,360.98%",-158.21%,-0.51%,27.52%,2.32M,0.10,-49.10%,3.39M,,124.41M,5.12,4.50%,159.0,0.0,,,1.81,20.7,,,Value,02110,Financial Services,"Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.",Boston,617-772-8500,MA,1388448000,United States,http://www.teklacap.com/hql.html,86400,100 Federal Street,617-772-8577,Asset Management,19th Floor
t-3,HQL,483570376.0,24279400,,,46430732,,46430732,1431334,606009,-825325,-825325,,,,,,0,606009,1431334,0,47256058,,46430732,46430732,356301677.0,595185.0,483570376.0,484165561.0,238832.0,4966000.0,127029867.0,59642860.0,,581242.0,5158511.0,419364190.0,165559.0,,13943.0,0,4577269.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1546214400,0.09153527,21.8276 - 22.02,0.0,0.0,21.85,10,13,finmb_352795,NYSE,Tekla Life Sciences Investors,USD,71673,73871,5.2700005,0.3174699,16.6 - 22.7,-0.8299999,-0.036563873,16.6,22.7,1.58,4.26815,0.072311215,USD,PRE,21.87,1630526402,0.020000458,21.95,22.02,21.8276,59448,us_market,2,0,0.06066922,TeklaLife Sciences Investors,NYQ,5.124,20.704,21.343714,0.5262871,0.02465771,20.619059,1.2509422,530990496,1.0563177,15,America/New_York,EDT,-14400000,False,False,0.95,,,22.7,16.6,21.34,20.62,71.67k,73.87k,24.28M,,,0.00%,19.87%,44.37k,0.53,,0.18%,54.08k,1.64,7.88%,1.58,7.23%,8.76,30.33%,"Dec 30, 2018","May 26, 2021",,,"Sep 29, 2020","Mar 30, 2021","5,360.98%",-158.21%,-0.51%,27.52%,2.32M,0.10,-49.10%,3.39M,,124.41M,5.12,4.50%,159.0,0.0,,,1.81,20.7,,,Value,02110,Financial Services,"Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.",Boston,617-772-8500,MA,1388448000,United States,http://www.teklacap.com/hql.html,86400,100 Federal Street,617-772-8577,Asset Management,19th Floor
